Positive Outlook for Phio Pharmaceuticals: Promising Clinical Results and Innovative Technology Drive Buy Rating

Analyst Vernon Bernardino of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals (PHIO – Research Report), with a price target of $4.00.

Vernon Bernardino has given his Buy rating due to a combination of factors influencing Phio Pharmaceuticals’ future growth prospects. One of the primary reasons is the promising results from the Phase 1b clinical study of PH-762, which targets PD-1 and has shown encouraging safety and tolerability. The study has demonstrated significant tumor clearance in patients with CSCC, and the absence of serious adverse events suggests a strong safety profile.
Additionally, the company’s INTASYL technology, which enhances the precision delivery of siRNA, has shown potential across multiple immunotherapeutic applications. This innovative approach has been showcased in recent scientific events, highlighting its role in boosting immune cell responses against cancer cells. The growing interest in INTASYL’s capabilities positions Phio Pharmaceuticals for potential partnerships and licensing agreements, which could further enhance its financial standing and market valuation.